Neuroprotective therapies for glaucoma

Drug Design, Development and Therapy

Volumn 9, Issue , 2015, Pages 1469-1479

  Song, Wei ^a   Huang, Ping ^a   Zhang, Chun ^a  

^a PEKING UNIVERSITY THIRD HOSPITAL   (China)

Author keywords

Glaucoma; Glaucomatous optic neuropathy; Neuroprotection; Retinal ganglion cells

Indexed keywords

ALPHA TOCOPHEROL; AMINOGUANIDINE; BRAIN DERIVED NEUROTROPHIC FACTOR; BRIMONIDINE; CILIARY NEUROTROPHIC FACTOR; DIZOCILPINE; GINKGO BILOBA EXTRACT; GLATIRAMER; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; LOMERIZINE; MEMANTINE; MINOCYCLINE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 1D7; NERVE GROWTH FACTOR; NEUROTROPHIC FACTOR; NILVADIPINE; NITRIC OXIDE; RECOMBINANT BRAIN DERIVED NEUROTROPHIC FACTOR; TETRANDRINE; TRIPTOLIDE; UBIDECARENONE; UNCLASSIFIED DRUG; NEUROPROTECTIVE AGENT;

APOPTOSIS; AUTOIMMUNITY; CELL ACTIVATION; CELL PROTECTION; DRUG EFFECT; DRUG RESPONSE; EXCITOTOXICITY; GLAUCOMA; GLAUCOMATOUS OPTIC NEUROPATHY; HUMAN; IMMUNOSTIMULATION; MICROGLIA; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OPTIC NERVE DISEASE; OXIDATIVE STRESS; REVIEW; TREATMENT OUTCOME; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; ANIMAL; DRUG EFFECTS; METABOLISM; PATHOLOGY;

ANIMALS; APOPTOSIS; GLAUCOMA; HUMANS; NEUROPROTECTIVE AGENTS;

EID: 84928251804     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S80594     Document Type: Review

References (85)

1. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90(3):262–267.
2. Casson RJ, Chidlow G, Wood JP, Crowston JG, Goldberg I. Definition of glaucoma: Clinical and experimental concepts. Clin Experiment Ophthalmol. 2012;40(4):341–349.
3. Shiose Y, Kitazawa Y, Tsukahara S, et al. Epidemiology of glaucoma in Japan – a nationwide glaucoma survey. Jpn J Ophthalmol. 1991;35(2):133–155.
4. Iwase A, Suzuki Y, Araie M, et al; Tajimi Study Group, Japan Glaucoma Society. The prevalence of primary open-angle glaucoma in Japanese: The Tajimi Study. Ophthalmology. 2004;111(9):1641–1648.
5. Narayanaswamy A, Baskaran M, Zheng Y, et al. The prevalence and types of glaucoma in an urban Indian population: The Singapore Indian Eye Study. Invest Ophthalmol Vis Sci. 2013;54(7):4621–4627.
6. Liang YB, Friedman DS, Zhou Q, et al. Prevalence of primary open angle glaucoma in a rural adult Chinese population: The Handan eye study. Invest Ophthalmol Vis Sci. 2011;21:52(11):8250–8257.
7. Levi-Montalcini R. The nerve growth factor 35 years later. Science. 1987;237(4819):1154–1162.
8. Chao MV. Neurotrophins and their receptors: A convergence point for many signalling pathways. Nat Rev Neurosci. 2003;4(4):299–309.
9. Adler R, Landa KB, Manthorpe M, Varon S. Cholinergic neuronotrophic factors: Intraocular distribution of trophic activity for ciliary neurons. Science. 1979;204(4400):1434–1436.
10. Henderson CE, Phillips HS, Pollock RA, et al. GDNF: A potent survival factor for motoneurons present in peripheral nerve and muscle. Science. 1994;266(5187):1062–1064.
11. Poo MM. Neurotrophins as synaptic modulators. Nat Rev. 2001;2(1):24–32.
12. Pease ME, McKinnon SJ, Quigley HA, Kerrigan-Baumrind LA, Zack DJ. Obstructed axonal transport of BDNF and its receptor TrkB in experimental glaucoma. Invest Ophthalmol Vis Sci. 2000;41(3):764–774.
13. Quigley HA, McKinnon SJ, Zack DJ, et al. Retrograde axonal transport of BDNF in retinal ganglion cells is blocked by acute IOP elevation in rats. Invest Ophthalmol Vis Sci. 2000;41(11):3460–3466.
14. Johnson EC, Deppmeier LM, Wentzien SK, Hsu I, Morrison JC. Chronology of optic nerve head and retinal responses to elevated intraocular pressure. Invest Ophthalmol Vis Sci. 2000;41(2):431–442.
15. Sposato V, Bucci MG, Coassin M, Russo MA, Lambiase A, Aloe L. Reduced NGF level and TrkA protein and TrkA gene expression in the optic nerve of rats with experimentally induced glaucoma. Neurosci Lett. 2008;446(1):20–24.
16. Ko ML, Hu DN, Ritch R, Sharma SC, Chen CF. Patterns of retinal ganglion cell survival after brain-derived neurotrophic factor administration in hypertensive eyes of rats. Neurosci Lett. 2001;305(2):139–142.
17. Martin KR, Quigley HA, Zack DJ, et al. Gene therapy with brain-derived neurotrophic factor as a protection: Retinal ganglion cells in a rat glaucoma model. Invest Ophthalmol Vis Sci. 2003;44(10):4357–4365.
18. Harper MM, Grozdanic SD, Blits B, et al. Transplantation of BDNF-secreting mesenchymal stem cells provides neuroprotection in chronically hypertensive rat eyes. Invest Ophthalmol Vis Sci. 2011;52(7):4506–4515.
19. Bai Y, Xu J, Brahimi F, Zhuo Y, Sarunic MV, Saragovi HU. An agonistic TrkB mAb causes sustained TrkB activation, delays RGC death, and protects the retinal structure in optic nerve axotomy and in glaucoma. Invest Ophthalmol Vis Sci. 2010;51(9):4722–4731.
20. Gao H, Qiao X, Cantor LB, WuDunn D. Up-regulation of brain-derived neurotrophic factor expression by brimonidine in rat retinal ganglion cells. Arch Ophthalmol. 2002;120(6):797–803.
21. Frank L, Ventimiglia R, Anderson K, Lindsay RM, Rudge JS. BDNF down-regulates neurotrophin responsiveness, TrkB protein and TrkB mRNA levels in cultured rat hippocampal neurons. Eur J Neurosci. 1996;8(6):1220–1230.
22. Lambiase A, Aloe L, Centofanti M, et al. Experimental and clinical evidence of neuroprotection by nerve growth factor eye drops: Implications for glaucoma. Proc Natl Acad Sci U S A. Epub 2009 Aug 3.
23. Ji JZ, Elyaman W, Yip HK, et al. CNTF promotes survival of retinal ganglion cells after induction of ocular hypertension in rats: The possible involvement of STAT3 pathway. Eur J Neurosci. 2004;19(2):265–272.
24. Zhang SS, Wei JY, Li C, Barnstable CJ, Fu XY. Expression and activation of STAT proteins during mouse retina development. Exp Eye Res. 2003;76(4):421–431.
25. Pease ME, Zack DJ, Berlinicke C, et al. Effect of CNTF on retinal ganglion cell survival in experimental glaucoma. Invest Ophthalmol Vis Sci. 2009;50(5):2194–2200.
26. Jiang C, Moore MJ, Zhang X, Klassen H, Langer R, Young M. Intravitreal injections of GDNF-loaded biodegradable microspheres are neuroprotective in a rat model of glaucoma. Mol Vis. 2007;13:1783–1792.
27. Manev H, Favaron M, Guidotti A, Costa E. Delayed increase of Ca2+ influx elicited by glutamate: Role in neuronal death. Mol Pharmacol. 1989;36(1):106–112.
28. Dreyer EB, Zurakowski D, Schumer RA, Podos SM, Lipton SA. Elevated glutamate levels in the vitreous body of humans and monkeys with glaucoma. Arch Ophthalmol. 1996;114(3):299–305.
29. Chaudhary P, Ahmed F, Sharma SC. MK801-a neuroprotectant in rat hypertensive eyes. Brain Res. 1998;792(1):154–158.
30. Nucci C, Tartaglione R, Rombolà L, Morrone LA, Fazzi E, Bagetta G. Neurochemical evidence to implicate elevated glutamate in the mechanisms of high intraocular pressure (IOP)-induced retinal ganglion cell death in rat. Neurotoxicology. 2005;26(5):935–941.
31. WoldeMussie E, Yoles E, Schwartz M, Ruiz G, Wheeler LA. Neuroprotective effect of memantine in different retinal injury models in rats. J Glaucoma. 2002;11(6):474–480.
32. Hare WA, WoldeMussie E, Lai RK, et al. Efficacy and safety of memantine treatment for reduction of changes associated with experimental glaucoma in monkey, I: Functional measures. Invest Ophthalmol Vis Sci. 2004;45(8):2625–2639.
33. Hare WA, WoldeMussie E, Weinreb RN, et al. Efficacy and safety of memantine treatment for reduction of changes associated with experimental glaucoma in monkey, II: Structural measures. Invest Ophthalmol Vis Sci. 2004;45(8):2640–2651.
34. Sena DF, Lindsley K. Neuroprotection for treatment of glaucoma in adults. Cochrane Database Syst Rev. 2013;2:CD006539.
35. Takahashi K, Lam TT, Edward DP, Buchi ER, Tso MO. Protective effects of flunarizine on ischemic injury in the rat retina. Arch Ophthalmol. 1992;110(6):862–870.
36. Osborne NN, Wood JP, Cupido A, Melena J, Chidlow G. Topical flunarizine reduces IOP and protects the retina against ischemia-excitotoxicity. Invest Ophthalmol Vis Sci. 2002;43(5):1456–1464.
37. Uemura A, Mizota A. Retinal concentration and protective effect against retinal ischemia of nilvadipine in rats. Eur J Ophthalmol. 2008;18(1):87–93.
38. Toriu N, Akaike A, Yasuyoshi H, et al. Lomerizine, a Ca2+ channel blocker, reduces glutamate-induced neurotoxicity and ischemia/reperfusion damage in rat retina. Exp Eye Res. 2000;70(4):475–484.
39. Koseki N, Araie M, Tomidokoro A, et al. A placebo-controlled 3-year study of a calcium blocker on visual field and ocular circulation in glaucoma with low-normal pressure. Ophthalmology. 2008;115(11):2049–2057.
40. Woo Cheon E, Hee Kim Y, Yun Cho Y, et al. Betaxolol, a beta1-adrenoceptor antagonist, protects a transient ischemic injury of the retina. Exp Eye Res. 2002;75(5):591–601.
41. Collignon-Brach J. Longterm effect of topical beta-blockers on intraocular pressure and visual field sensitivity in ocular hypertension and chronic open-angle glaucoma. Surv Ophthalmol. 1994;38(Suppl):S149–S155.
42. Elmore S. Apoptosis: A review of programmed cell death. Toxicol Pathol. 2007;35(4):495–516.
43. Quigley HA, Nickells RW, Kerrigan LA, Pease ME, Thibault DJ, Zack DJ. Retinal ganglion cell death in experimental glaucoma and after axotomy occurs by apoptosis. Invest Ophthalmol Vis Sci. 1995;36(5):774–786.
44. Kerrigan LA, Zack DJ, Quigley HA, Smith SD, Pease ME. TUNEL-positive ganglion cells in human primary open-angle glaucoma. Arch Ophthalmol. 1997;115(8):1031–1035.
45. Roh M, Zhang Y, Murakami Y, et al. Etanercept, a widely used inhibitor of tumor necrosis factor-alpha (TNF-alpha), prevents retinal ganglion cell loss in a rat model of glaucoma. PLoS One. 2012;7(7):e40065.
46. Huang W, Fileta JB, Dobberfuhl A, et al. Calcineurin cleavage is triggered by elevated intraocular pressure, and calcineurin inhibition blocks retinal ganglion cell death in experimental glaucoma. Proc Natl Acad Sci U S A. 2005;102(34):12242–12247.
47. McKinnon SJ, Lehman DM, Tahzib NG, et al. Baculoviral IAP repeat-containing-4 protects optic nerve axons in a rat glaucoma model. Mol Ther. 2002;5(6):780–787.
48. Tatton W, Chen D, Chalmers-Redman R, Wheeler L, Nixon R, Tatton N. Hypothesis for a common basis for neuroprotection in glaucoma and Alzheimer’s disease: Anti-apoptosis by alpha-2-adrenergic receptor activation. Surv Ophthalmol. 2003;48(Suppl 1):S25–S37.
49. Levkovitch-Verbin H, Waserzoog Y, Vander S, Makarovsky D, Piven I. Minocycline upregulates pro-survival genes and downregulates pro-apoptotic genes in experimental glaucoma. Graefes Arch Clin Exp Ophthalmol. 2014;252(5):761–772.
50. Izzotti A, Sacca SC, Cartiglia C, De Flora S. Oxidative deoxyribonucleic acid damage in the eyes of glaucoma patients. Am J Med. 2003;114(8):638–646.
51. Aydemir O, Naziroglu M, Celebi S, Yilmaz T, Kukner AS. Antioxidant effects of alpha-, gamma-and succinate-tocopherols in guinea pig retina during ischemia-reperfusion injury. Pathophysiology. 2004;11(3):167–171.
52. Dilsiz N, Sahaboglu A, Yildiz MZ, Reichenbach A. Protective effects of various antioxidants during ischemia-reperfusion in the rat retina. Graefes Arch Clin Exp Ophthalmol. 2006;244(5):627–633.
53. Nucci C, Tartaglione R, Cerulli A, et al. Retinal damage caused by high intraocular pressure-induced transient ischemia is prevented by coenzyme Q10 in rat. Int Rev Neurobiol. 2007;82:397–406.
54. Lee D, Shim MS, Kim KY, et al. Coenzyme Q10 inhibits glutamate excitotoxicity and oxidative stress-mediated mitochondrial alteration in a mouse model of glaucoma. Invest Ophthalmol Vis Sci. 2014;55(2):993–1005.
55. Nebbioso M, Scarsella G, Tafani M, Pescosolido N. Mechanisms of ocular neuroprotection by antioxidant molecules in animal models. J Biol Regul Homeost Agents. 2013;27(1):197–209.
56. Hirooka K, Tokuda M, Miyamoto O, Itano T, Baba T, Shiraga F. The Ginkgo biloba extract (EGb 761) provides a neuroprotective effect on retinal ganglion cells in a rat model of chronic glaucoma. Curr Eye Res. 2004;28(3):153–157.
57. Quaranta L, Bettelli S, Uva MG, Semeraro F, Turano R, Gandolfo E. Effect of Ginkgo biloba extract on preexisting visual field damage in normal tension glaucoma. Ophthalmology. 2003;110(2):359–362; Discussion. 362–354.
58. Lee J, Sohn SW, Kee C. Effect of Ginkgo biloba extract on visual field progression in normal tension glaucoma. J Glaucoma. 2013;22(9):780–784.
59. Droy-Lefaix MT, Cluzel J, Menerath JM, Bonhomme B, Doly M. Antioxidant effect of a Ginkgo biloba extract (EGb 761) on the retina. Int J Tissue React. 1995;17(3):93–100.
60. Guo X, Kong X, Huang R, et al. Effect of Ginkgo biloba on visual field and contrast sensitivity in Chinese patients with normal tension glaucoma: A randomized, crossover clinical trial. Invest Ophthalmol Vis Sci. 2014;55(1):110–116.
61. Chan HC, Chang RC, Koon-Ching Ip A, et al. Neuroprotective effects of Lycium barbarum Lynn on protecting retinal ganglion cells in an ocular hypertension model of glaucoma. Exp Neurol. 2007;203(1):269–273.
62. Li H, Liang Y, Chiu K, et al. Lycium barbarum (wolfberry) reduces secondary degeneration and oxidative stress, and inhibits JNK pathway in retina after partial optic nerve transection. PLoS One. 2013;8(7):e68881.
63. Neufeld AH, Hernandez MR, Gonzalez M. Nitric oxide synthase in the human glaucomatous optic nerve head. Arch Ophthalmol. 1997;115(4):497–503.
64. Liu B, Neufeld AH. Expression of nitric oxide synthase-2 (NOS-2) in reactive astrocytes of the human glaucomatous optic nerve head. Glia. 2000;30(2):178–186.
65. Neufeld AH. Microglia in the optic nerve head and the region of parapapillary chorioretinal atrophy in glaucoma. Arch Ophthalmol. 1999;117(8):1050–1056.
66. Neufeld AH. Pharmacologic neuroprotection with an inhibitor of nitric oxide synthase for the treatment of glaucoma. Brain Res Bull. 2004;62(6):455–459.
67. Neufeld AH, Das S, Vora S, et al. A prodrug of a selective inhibitor of inducible nitric oxide synthase is neuroprotective in the rat model of glaucoma. J Glaucoma. 2002;11(3):221–225.
68. Neufeld AH, Kawai S, Das S, et al. Loss of retinal ganglion cells following retinal ischemia: The role of inducible nitric oxide synthase. Exp Eye Res. 2002;75(5):521–528.
69. Streit WJ. Microglia as neuroprotective, immunocompetent cells of the CNS. Glia. 2002;40(2):133–139.
70. Levkovitch-Verbin H, Kalev-Landoy M, Habot-Wilner Z, Melamed S. Minocycline delays death of retinal ganglion cells in experimental glaucoma and after optic nerve transection. Arch Ophthalmol. 2006;124(4):520–526.
71. Bosco A, Inman DM, Steele MR, et al. Reduced retina microglial activation and improved optic nerve integrity with minocycline treatment in the DBA/2J mouse model of glaucoma. Invest Ophthalmol Vis Sci. 2008;49(4):1437–1446.
72. Su W, Li Z, Jia Y, Zhuo Y. Rapamycin is neuroprotective in a rat chronic hypertensive glaucoma model. PLoS One. 2014;9(6):e99719.
73. Yang F, Wu L, Guo X, Wang D, Li Y. Improved retinal ganglion cell survival through retinal microglia suppression by a chinese herb extract, triptolide, in the DBA/2J mouse model of glaucoma. Ocul Immunol Inflamm. 2013;21(5):378–389.
74. Li W, Yang C, Lu J, et al. Tetrandrine protects mouse retinal ganglion cells from ischemic injury. Drug Des Devel Ther. 2014;8:327–339.
75. Dang Y, Xu Y, Wu W, et al. Tetrandrine suppresses lipopolysaccharide-induced microglial activation by inhibiting NF-kappaB and ERK signaling pathways in BV2 cells. PLoS One. 2014;9(8):e102522.
76. Graber JJ, Dhib-Jalbut S. Protective autoimmunity in the nervous system. Pharmacol Ther. 2009;121(2):147–159.
77. Schwartz M. Neurodegeneration and neuroprotection in glaucoma: development of a therapeutic neuroprotective vaccine: The Friedenwald lecture. Invest Ophthalmol Vis Sci. 2003;44(4):1407–1411.
78. Schori H, Kipnis J, Yoles E, et al. Vaccination for protection of retinal ganglion cells against death from glutamate cytotoxicity and ocular hypertension: Implications for glaucoma. Proc Natl Acad Sci U S A. 2001;98(6):3398–3403.
79. Bakalash S, Kessler A, Mizrahi T, Nussenblatt R, Schwartz M. Antigenic specificity of immunoprotective therapeutic vaccination for glaucoma. Invest Ophthalmol Vis Sci. 2003;44(8):3374–3381.
80. Ben Simon GJ, Bakalash S, Aloni E, Rosner M. A rat model for acute rise in intraocular pressure: Immune modulation as a therapeutic strategy. Am J Ophthalmol. 2006;141(6):1105–1111.
81. Yang B, Shan L, Song W, Xiao Z, Shi L, Yuan H. Copolymer-1 immunization reduces damage in retinal ganglion cells under high intraocular pressure through altering the expression of retinal neurotrophins. J Ocul Pharmacol Ther. 2010;26(1):11–19.
82. Zhou X, Xia XB, Xiong SQ. Neuro-protection of retinal stem cells transplantation combined with copolymer-1 immunization in a rat model of glaucoma. Mol Cell Neurosci. 2013;54:1–8.
83. Wheeler LA, Gil DW, Wolde Mussie E. Role of alpha-2 adrenergic receptors in neuroprotection and glaucoma. Surv Ophthalmol. 2001;45(Suppl 3):S290–S294; Discussion S295–S296.
84. Krupin T, Liebmann JM, Greenfield DS, Ritch R, Gardiner S; Low-Pressure Glaucoma Study Group. A randomized trial of brimonidine versus timolol in preserving visual function: Results from the Low-Pressure Glaucoma Treatment Study. Am J Ophthalmol. 2011;151(4):671–681.
85. Liu Y, Pang IH. Challenges in the development of glaucoma neuroprotection therapy. Cell Tissue Res. 2013;353(2):253–260.